|Videos|March 30, 2022
Urology Times 50 Innovations Series: Treatment of female hypoactive sexual desire disorder
Author(s)Urology Times staff
"We as urologists are board certified to take care of all genders. We are really good sexual medicine doctors, and we need to apply what we know about sexual medicine, not just for our male patients, but for all of our patients," says Rachel S. Rubin, MD
Advertisement
As part of the Urology Times' 50th Anniversary Innovation Celebration, Rachel S. Rubin, MD, discusses the evolution in the treatment of female hypoactive sexual desire disorder. Rubin is a board-certified urologist with fellowship training in sexual medicine. She is an assistant clinical professor in urology at Georgetown University and recently started a private practice in the Washington DC area.
Advertisement
Related to this article
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
A recap of the FDA submissions and regulatory decisions in urology from September 2026.
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Advertisement
Advertisement
Trending on Urology Times
1
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
2
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
3
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
4
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
5